##gff-version 3
##sequence-region Q9H165 1 835
Q9H165	UniProtKB	Chain	1	835	.	.	.	ID=PRO_0000047102;Note=B-cell lymphoma/leukemia 11A	
Q9H165	UniProtKB	Zinc finger	170	193	.	.	.	Note=C2H2-type 1;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00042	
Q9H165	UniProtKB	Zinc finger	377	399	.	.	.	Note=C2H2-type 2;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00042	
Q9H165	UniProtKB	Zinc finger	405	429	.	.	.	Note=C2H2-type 3;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00042	
Q9H165	UniProtKB	Zinc finger	742	764	.	.	.	Note=C2H2-type 4;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00042	
Q9H165	UniProtKB	Zinc finger	770	792	.	.	.	Note=C2H2-type 5;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00042	
Q9H165	UniProtKB	Zinc finger	800	823	.	.	.	Note=C2H2-type 6;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00042	
Q9H165	UniProtKB	Region	1	210	.	.	.	Note=Required for nuclear body formation and for SUMO1 recruitment;Ontology_term=ECO:0000250;evidence=ECO:0000250	
Q9H165	UniProtKB	Compositional bias	260	373	.	.	.	Note=Pro-rich	
Q9H165	UniProtKB	Compositional bias	481	509	.	.	.	Note=Glu-rich	
Q9H165	UniProtKB	Modified residue	86	86	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q9QYE3	
Q9H165	UniProtKB	Modified residue	205	205	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:19369195;Dbxref=PMID:19369195	
Q9H165	UniProtKB	Modified residue	271	271	.	.	.	Note=Asymmetric dimethylarginine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q9QYE3	
Q9H165	UniProtKB	Modified residue	332	332	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:19690332;Dbxref=PMID:19690332	
Q9H165	UniProtKB	Modified residue	337	337	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q9QYE3	
Q9H165	UniProtKB	Modified residue	446	446	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q9QYE3	
Q9H165	UniProtKB	Modified residue	447	447	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q9QYE3	
Q9H165	UniProtKB	Modified residue	608	608	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:19369195;Dbxref=PMID:19369195	
Q9H165	UniProtKB	Modified residue	625	625	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:19690332;Dbxref=PMID:19690332	
Q9H165	UniProtKB	Modified residue	630	630	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:19690332;Dbxref=PMID:19690332	
Q9H165	UniProtKB	Modified residue	701	701	.	.	.	Note=Phosphothreonine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:19690332;Dbxref=PMID:19690332	
Q9H165	UniProtKB	Cross-link	123	123	.	.	.	Note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2);Ontology_term=ECO:0000244,ECO:0000244;evidence=ECO:0000244|PubMed:25755297,ECO:0000244|PubMed:28112733;Dbxref=PMID:25755297,PMID:28112733	
Q9H165	UniProtKB	Cross-link	164	164	.	.	.	Note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2);Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:28112733;Dbxref=PMID:28112733	
Q9H165	UniProtKB	Cross-link	620	620	.	.	.	Note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2);Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:28112733;Dbxref=PMID:28112733	
Q9H165	UniProtKB	Cross-link	634	634	.	.	.	Note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1);Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q9QYE3	
Q9H165	UniProtKB	Cross-link	833	833	.	.	.	Note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2);Ontology_term=ECO:0000244,ECO:0000244;evidence=ECO:0000244|PubMed:25755297,ECO:0000244|PubMed:28112733;Dbxref=PMID:25755297,PMID:28112733	
Q9H165	UniProtKB	Alternative sequence	129	163	.	.	.	ID=VSP_009548;Note=In isoform 6. DKLLHWRGLSSPRSAHGALIPTPGMSAEYAPQGIC->G;Ontology_term=ECO:0000303;evidence=ECO:0000303|Ref.2	
Q9H165	UniProtKB	Alternative sequence	129	142	.	.	.	ID=VSP_058656;Note=In isoform 7. DKLLHWRGLSSPRS->AQTELEDVFVYLMV	
Q9H165	UniProtKB	Alternative sequence	143	835	.	.	.	ID=VSP_058657;Note=In isoform 7. Missing	
Q9H165	UniProtKB	Alternative sequence	212	243	.	.	.	ID=VSP_009550;Note=In isoform 3. GIPSGLGAECPSQPPLHGIHIADNNPFNLLRI->LHTPPFGVVPRELKMCGSFRMEAREPLSSEKI;Ontology_term=ECO:0000303;evidence=ECO:0000303|PubMed:11719382;Dbxref=PMID:11719382	
Q9H165	UniProtKB	Alternative sequence	244	835	.	.	.	ID=VSP_009552;Note=In isoform 3. Missing;Ontology_term=ECO:0000303;evidence=ECO:0000303|PubMed:11719382;Dbxref=PMID:11719382	
Q9H165	UniProtKB	Alternative sequence	745	773	.	.	.	ID=VSP_009554;Note=In isoform 2. EYCGKVFKNCSNLTVHRRSHTGERPYKCE->SSHTPIRRSTQRAQDVWQFSDGSSRALKF;Ontology_term=ECO:0000303,ECO:0000303,ECO:0000303;evidence=ECO:0000303|PubMed:11347906,ECO:0000303|PubMed:11719382,ECO:0000303|PubMed:15489334;Dbxref=PMID:11347906,PMID:11719382,PMID:15489334	
Q9H165	UniProtKB	Alternative sequence	774	835	.	.	.	ID=VSP_009555;Note=In isoform 2. Missing;Ontology_term=ECO:0000303,ECO:0000303,ECO:0000303;evidence=ECO:0000303|PubMed:11347906,ECO:0000303|PubMed:11719382,ECO:0000303|PubMed:15489334;Dbxref=PMID:11347906,PMID:11719382,PMID:15489334	
Q9H165	UniProtKB	Natural variant	47	47	.	.	.	ID=VAR_076921;Note=In IDPFH%3B de novo mutation%3B loss of function in transactivation of transcription%3B reduces the interaction between isoform 2 and isoform 3%3B disrupts the nuclear paraspeckle distribution of isoform 2 and isoform 3. T->P;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:27453576;Dbxref=dbSNP:rs886037864,PMID:27453576	
Q9H165	UniProtKB	Natural variant	48	48	.	.	.	ID=VAR_076922;Note=In IDPFH%3B de novo mutation%3B loss of function in transactivation of transcription%3B reduces the interaction between isoform 2 and isoform 3%3B disrupts the nuclear paraspeckle distribution of isoform 2 and isoform 3. C->F;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:27453576;Dbxref=dbSNP:rs886037865,PMID:27453576	
Q9H165	UniProtKB	Natural variant	66	66	.	.	.	ID=VAR_076923;Note=In IDPFH%3B de novo mutation%3B loss of function in transactivation of transcription%3B reduces the interaction between isoform 2 and isoform 3%3B disrupts the nuclear paraspeckle distribution of isoform 2 and isoform 3. H->Q;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:27453576;Dbxref=dbSNP:rs886037866,PMID:27453576	
Q9H165	UniProtKB	Natural variant	142	142	.	.	.	ID=VAR_035553;Note=In a breast cancer sample%3B somatic mutation. S->F;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:16959974;Dbxref=PMID:16959974	
Q9H165	UniProtKB	Sequence conflict	119	119	.	.	.	Note=G->R;Ontology_term=ECO:0000305;evidence=ECO:0000305	
Q9H165	UniProtKB	Sequence conflict	119	119	.	.	.	Note=G->R;Ontology_term=ECO:0000305;evidence=ECO:0000305	
Q9H165	UniProtKB	Sequence conflict	119	119	.	.	.	Note=G->R;Ontology_term=ECO:0000305;evidence=ECO:0000305	
Q9H165	UniProtKB	Sequence conflict	316	316	.	.	.	Note=S->F;Ontology_term=ECO:0000305;evidence=ECO:0000305	
Q9H165	UniProtKB	Sequence conflict	386	386	.	.	.	Note=F->L;Ontology_term=ECO:0000305;evidence=ECO:0000305	
Q9H165	UniProtKB	Sequence conflict	522	532	.	.	.	Note=Missing;Ontology_term=ECO:0000305;evidence=ECO:0000305	
Q9H165	UniProtKB	Sequence conflict	648	648	.	.	.	Note=A->T;Ontology_term=ECO:0000305;evidence=ECO:0000305	
Q9H165	UniProtKB	Sequence conflict	648	648	.	.	.	Note=A->T;Ontology_term=ECO:0000305;evidence=ECO:0000305	
Q9H165	UniProtKB	Sequence conflict	653	653	.	.	.	Note=E->D;Ontology_term=ECO:0000305;evidence=ECO:0000305	
Q9H165	UniProtKB	Sequence conflict	730	730	.	.	.	Note=P->T;Ontology_term=ECO:0000305;evidence=ECO:0000305	
Q9H165	UniProtKB	Sequence conflict	730	730	.	.	.	Note=P->T;Ontology_term=ECO:0000305;evidence=ECO:0000305	
